This concept is strongly supported by experimental data indicating an anti-inflammatory effect for HDAC inhibitors in murine models of chronic inflammation such as rheumatoid arthritis 9, hepatitis 10 and various models of colitis 11 or inflammation-associated cancer 12. Here, HDAC9 is linked to cancer.